Version 1
: Received: 1 October 2024 / Approved: 10 October 2024 / Online: 11 October 2024 (10:31:33 CEST)
How to cite:
Arivarasan, V. K.; Karthik, R.; Gangarapu, K.; Suman, S.; P, S.; M.S., S. D. Glycemic Control Efficacy of ‘Avaram Amrit’ in Type 2 Diabetes Mellitus: A 12-Week Open-Label Clinical Trial. Preprints2024, 2024100846. https://doi.org/10.20944/preprints202410.0846.v1
Arivarasan, V. K.; Karthik, R.; Gangarapu, K.; Suman, S.; P, S.; M.S., S. D. Glycemic Control Efficacy of ‘Avaram Amrit’ in Type 2 Diabetes Mellitus: A 12-Week Open-Label Clinical Trial. Preprints 2024, 2024100846. https://doi.org/10.20944/preprints202410.0846.v1
Arivarasan, V. K.; Karthik, R.; Gangarapu, K.; Suman, S.; P, S.; M.S., S. D. Glycemic Control Efficacy of ‘Avaram Amrit’ in Type 2 Diabetes Mellitus: A 12-Week Open-Label Clinical Trial. Preprints2024, 2024100846. https://doi.org/10.20944/preprints202410.0846.v1
APA Style
Arivarasan, V. K., Karthik, R., Gangarapu, K., Suman, S., P, S., & M.S., S. D. (2024). Glycemic Control Efficacy of ‘Avaram Amrit’ in Type 2 Diabetes Mellitus: A 12-Week Open-Label Clinical Trial. Preprints. https://doi.org/10.20944/preprints202410.0846.v1
Chicago/Turabian Style
Arivarasan, V. K., Sathyarajeswaran P and Shree Devi M.S.. 2024 "Glycemic Control Efficacy of ‘Avaram Amrit’ in Type 2 Diabetes Mellitus: A 12-Week Open-Label Clinical Trial" Preprints. https://doi.org/10.20944/preprints202410.0846.v1
Abstract
Background: Avaram Amrit, derived from a traditional medicinal plant, has shown potential in diabetes management. This study aimed to evaluate its clinical efficacy in glycemic control. Methods: A 12-week, open-label clinical trial was conducted with 9 type 2 diabetes patients. Participants received Avaram Amrit extract daily. Fasting and postprandial glucose levels were measured bi-weekly, with HbA1c assessed at baseline and week 12. Results: Fasting glucose levels decreased significantly from 252.54 ± 71.99 mg/dL at baseline to 195.50 ± 55.01 mg/dL at week 12 (p<0.001), representing a 22.6% reduction. Mean HbA1c decreased by 1.25 percentage points. Postprandial glucose levels showed consistent improvement across the study period. A strong positive correlation was observed between initial HbA1c and fasting glucose (r=0.89). Conclusion: Avaram Amrit demonstrated significant improvement in glycemic control over 12 weeks. The consistent decrease in both short-term (glucose levels) and long-term (HbA1c) measures indicates a positive response to the intervention. While promising, larger randomized controlled trials are necessary to confirm these findings and establish Avaram Amrit's role in diabetes management.
Biology and Life Sciences, Biology and Biotechnology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
